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Abstract
Platelet-rich plasma (PRP) contains growth factors 
that promote tissue regeneration. Previously, we 
showed that heparin-conjugated fibrin (HCF) exerts 
the sustained release of growth factors with affinity for 
heparin. Here, we hypothesize that treatment of skin 
wound with a mixture of PRP and HCF exerts sustained 
release of several growth factors contained in PRP and 
promotes skin wound healing. The release of fibroblast 
growth factor 2, platelet-derived growth factor-BB, and 
vascular endothelial growth factor contained in PRP 
from HCF was sustained for a longer period than those 
from PRP, calcium-activated PRP (C-PRP), or a mixture 
of fibrin and PRP (F-PRP). Treatment of full-thickness 
skin wounds in mice with HCF-PRP resulted in much 
faster wound closure as well as dermal and epidermal 
regeneration at day 12 compared to treatment with ei-
ther C-PRP or F-PRP. Enhanced skin regeneration ob-
served in HCF-PRP group may have been at least parti-
ally due to enhanced angiogenesis in the wound beds. 
Therefore, this method could be useful for skin wound 
treatment.
Keywords: angiogenesis inducing agents; endothe-
lial growth factors; fibrin; fibroblast growth factor 2; 
heparin; neovascularization, physiologic; platelet- 
derived growth factor; platelet-rich plasma; wound 
healing
Introduction
Clinical interest in platelet-rich plasma (PRP) stems 
from its potential as a safe and easily attainable 
source of the wide range of growth factors (GFs) 
and cytokines required in physiological tissue 
repair. PRP contains not only a number of GFs, 
including platelet-derived growth factor (PDGF), 
vascular endothelial growth factor (VEGF), 
transforming growth factor (TGF)-β, insulin-like 
growth factor (IGF), and fibroblast growth factor 
(FGF)-2, but also cytokines and inflammatory 
mediators (Rozman and Bolta, 2007). Unfortunately, 
the clinical evidence for PRP as a therapeutic agent 
is insufficient (Froum et al., 2002; Raghoebar et al., 
2005) due to obstacles such as rapid washout 
(Tsay et al., 2005) and inactivation (Bir et al., 2009) 
of the critical proteins in PRP. However, there have 
been a few studies on the sustained delivery of 
GFs contained in PRP whose aims were to prevent 
initial washout and control the release of important 
proteins in PRP to the concerned area (Hokugo et 
al., 2005).
    Various heparin-conjugated biomaterials have 
been utilized as a GF delivery vehicle (Jeon et al., 
2006; Thomopoulos et al., 2010; Yang et al., 2010a, 
2010b) by mimicking the physiological function of 
heparin sulfate (HS), which is abundant in the 
extracellular matrix (ECM). During healing, GFs 
are detached from and HS boosts the effect of the 
GFs (Schultz and Wysocki, 2009). Heparin, a well- 
known anticoagulant, is closely related to HS in a 
structural sense and can also bind to various GFs, 
including VEGF (Iozzo and San Antonio, 2001), 
PDGF (Chu et al., 2004), and FGF2 (Schultz and 
Wysocki, 2009). Previously, we developed 
heparin-conjugated fibrin (HCF) and showed that 
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Figure 1. Release of various GFs contained in PRP from various deliv-
ery systems. (A) The concentrations of GFs in PRP. Kinetics of release of 
(B) PDGF-BB, (C) VEGF, and (D) FGF2 from various delivery systems in 
vitro. Values represent the mean± standard deviation (n = 3). *P＜
0.05 compared to any group. #P＜ 0.001 compared to any group.
Figure 2. The bioactivity of GFs in PRP released from various delivery 
systems. Bioactivity of the GFs was evaluated by measuring their ability 
to stimulate HDF growth in vitro. Values represent the mean± standard 
deviation (n = 3). *P＜ 0.05 compared to any group. #P＜ 0.01 com-
pared to any group.
HCF can provide superior tissue regeneration 
properties to fibrin-based carriers by releasing 
bone morphogenic protein-2 (Yang et al., 2010b) 
and FGF2 (Yang et al., 2010a) for long time periods. 
In the present study, we have adopted HCF as a 
PRP carrier system and used it to make 
comparisons with other carrier systems both in 
vitro and in vivo. We first examined the release 
kinetics of GFs contained in PRP from HCF and 
fibrin-based carriers. Among the GFs contained in 
PRP, release of PDGF-BB, VEGF, and FGF2 was 
evaluated since these GFs can bind to heparin in 
HCF (Yang et al., 2010a, 2010b) and are known to 
stimulate angiogenesis (Yang et al., 2010a), which 
promotes skin wound healing (Tonnesen et al., 
2000). Activities of GFs released from the carriers 
were evaluated by determining the growth of human 
dermal fibroblasts (HDFs) cultured in the presence 
of GF delivery systems. To determine whether or 
not the delivery of GFs contained in PRP with HCF 
enhances wound healing as compared to calcium- 
activated PRP (C-PRP) or a mixture of fibrin and 
PRP (F-PRP), full-thickness skin wounds in mice 
were treated with HCF-PRP, C-PRP, or F-PRP. 
Calcium was added to PRP in C-PRP group to 
induce platelets in PRP to release growth factors 
(Frechette et al., 2005). Fibrin was added to PRP 
in F-PRP group to enhance gel formation. Twelve 
days after treatment, skin wound healing was 
evaluated based on histology, morphometric analysis, 
immunohistochemistry, and reverse transcription 
polymerase chain reaction (RT-PCR).
Results
In vitro GF release
As determined by enzyme-linked immunosorbent 
assay (ELISA), PRP contained 1628.0±381.3 
ng/ml of PDGF-BB, 76.2±12.9 pg/ml of VEGF, 
and 37.9±7.8 pg/ml of FGF2 (Figure 1A). Most of 
PDGF-BB, VEGF, and FGF2 contained in PRP 
were released within 6 h when no carrier was used 
(Figures 1A-1D). The initial burst release and 
release period differed depending on the type of 
delivery system (Figures 1B-1D). The initial burst 
release for PDGF-BB and VEGF in the first 6 h 
from PRP, C-PRP, and F-PRP was larger than that 
from HCF-PRP. HCF-PRP released 69.3± 3.2% of 
PDGF-BB within 6 days, whereas approximately 
the same amount was released from C-PRP and 
F-PRP within 6 h and 3 days, respectively. HCF-PRP 
released 63.6± 5.8% of VEGF within 9 days, 
whereas approximately the same amount was 
released from C-PRP and F-PRP within 6 h.
Bioactivity of GFs released from delivery systems
The bioactivity of GFs released from the delivery 
systems was evaluated by determining their ability 
to stimulate HDF growth in the presence of each 
delivery system. HCF (containing no PRP) and 
PRP showed no cell growth (Figure 2). Cell 
number increased until day 8 and thereafter 
decreased in both C-PRP and F-PRP. In contrast, 
HCF-PRP resulted in sustained cell growth within 
the range of observation (12 days).
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Figure 3. Wound closure. (A) Representative photographs of full-thick-
ness skin wounds at various time points after treatment with PRP + vari-
ous delivery systems. The dotted lines indicate the original wound 
margin. The dotted circles indicate the knots of stitches. (B) Wound clo-
sure rates. *P＜ 0.05 compared to any other group.
Figure 4. Histological analyses of wound healing. Masson’s 
Trichrome-stained sections of wounds (A) at a low magnification and (B) 
at a high magnification at 12 days after treatment with PRP + various de-
livery systems. The dotted squares indicate the mid portion used in (B). 
Ep, epithelium; De, dermis; h, hair follicle; Gr, granulation tissue; Mu, 
muscle layer; Sc, subcutaneous tissue; St, scar tissue; He, hypertrophic 
epithelium. (C) Graphic illustration of wound healing. (D) Wound edge 
distance (i.e., distance between tips of epithelium), hypertrophic cover-
age, and inter-SC distance in wounds at 12 days after treatment with 
PRP + various delivery systems. *P＜ 0.001 compared to F-PRP or 
HCF-PRP. **P＜ 0.05 compared to HCF-PRP.
Macroscopic wound closure
The wound area at various times points was 
expressed as a percentage relative to the original 
wound size. Four days after treatment, the wound 
area was not significantly different among the 
groups (Figure 3). At day 8 and 12, HCF-PRP 
group showed significantly smaller wound size 
(69.6± 8.4%, 21.2±4.6%) compared to the other 
groups. The wound sizes of C-PRP and F-PRP 
groups were not significantly different from those of 
no treatment group at day 8 and day 12.
Histological observation
Masson’s trichrome staining of histological sections 
of tissue taken from the center of the healed 
wounds at day 12 indicated that among the groups, 
HCF-PRP showed a histological structure most 
similar to that of normal skin (Figures 4A and 4B). 
Three different histological criteria were applied to 
quantitatively evaluate wound healing: hypertrophic 
coverage, distances between the epithelial tips, 
and subcutaneous tissue (SC) edges (Figure 4C). 
Twelve days after treatment, F-PRP and HCF-PRP 
showed almost complete epithelialization in the 
wound area, whereas no treatment and C-PRP 
groups still contained gaps of several millimeters 
between the epithelial tips (Figure 4D). Distances 
between the edges of SCs in HCF-PRP group 
were significantly smaller than those in the other 
three groups (Figure 4D).
Epithelial regeneration
Epithelial maturation was evaluated by immuno-
fluorescent staining for mouse involucrin at the 
mid-portion of the wound at day 12 (Figure 5A). No 
treatment at day 0 revealed no involucrin staining. 
HCF-PRP group showed an expression pattern for 
involucrin that was similar to that of normal skin. 
No treatment, C-PRP, and F-PRP groups showed 
only small amounts of involucrin expression. The 
expression level of matrix metalloprotease (MMP)-9, 
which is induced during keratinocyte migration 
(McCawley et al., 1998), in the wound beds was 
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Figure 6. Neovascularization in the wounds at 12 days after treatment 
with PRP + various delivery systems. Immunohistochemical staining with 
anti-SM α-actin antibodies. Green and blue (DAPI) indicate the walls of 
arterioles and nucleus, respectively. Scale bars indicate 100 μm. 
Arteriole density was quantified. *P＜ 0.05 compared to any other 
group.
Figure 5. Epithelial regeneration in full-thickness skin wounds at 12 days 
after treatment with PRP + various delivery systems. (A) Immunohisto-
chemical staining with anti-involucrin antibodies of treated wound 
sections. Red and blue (DAPI) indicate differentiated epithelial layer and 
nucleus, respectively. Scale bars indicate 100 μm. (B) RT-PCR analysis 
for MMP-9 expression in the wounds at 12 days after treatment with PRP
+ various delivery systems.
Figure 7. Neovascularization in the wounds at 12 days after treatment 
with PRP + various delivery systems. Immunohistochemical staining with 
anti-vWF antibodies. Green and blue (DAPI) indicate the walls of capil-
laries and nucleus, respectively. Scale bars indicate 100 μm. The capil-
lary density was quantified. *P＜ 0.05 compared to any other group.
higher in HCF-PRP group compared to the other 
groups (Figure 5B). In no treatment and C-PRP 
groups, MMP-9 expression was below the detection 
range.
Angiogenesis
HCF-PRP enhanced angiogenesis at the wound 
beds as compared to no treatment, C-PRP, and 
F-PRP groups. Immunofluorescent staining for mouse 
smooth muscle (SM) α-actin and quantification of 
arteriole density revealed that arteriole density was 
significantly enhanced by HCF-PRP treatment (3.8
±1.4/mm2) as compared to no treatment (0.0±
0.0/mm2), C-PRP (0.6±1.0/mm2), and F-PRP (0.3
±0.6/mm2) groups (Figure 6). Immunofluorescent 
staining for mouse von Willebrand Factor (vWF) 
and quantification of capillary density revealed that 
HCF-PRP significantly enhanced capillary density 
(16.3± 5.7/mm2) as compared to no treatment 
(0.0±0.0/mm2), C-PRP (0.0±0.0/mm2), and 
F-PRP (0.4± 0.7/mm2) groups (Figure 7).
Discussion
Although PRP is an inexpensive and immunologically 
safe source of GFs, the tissue regeneration 
efficacy of PRP has been controversial (Froum et 
al., 2002; Raghoebar et al., 2005) because of the 
rapid inactivation and initial burst of GFs contained 
in the PRP. During physiological wound healing, an 
important role of extracellular matrix (ECM) is to 
preserve GFs in an active state and release them 
when necessary (Tonnesen et al., 2000). In order 
to preserve GF activity and secrete them to wound 
sites, we used HCF as a carrier for GFs contained 
in PRP, since HS, a natural analogue of heparin, is 
involved in the storage of GFs inside the ECM 
(Chu et al., 2004; Schultz and Wysocki, 2009). The 
use of PRP-HCF for tissue regeneration mimics 
the physiological tissue regeneration process, 
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since PRP contains a wide spectrum of the GFs 
and cytokines required for tissue regeneration and 
HCF can mimic the role of ECM for GF release.
    PRP also contains FGF2 (Bennett and Schultz, 
1993; Marui et al., 2005). Studies have suggested 
that exogenously administrated FGF2 can 
enhance the regeneration of connective tissue in 
dermal wound healing models with enhance 
angiogenesis (Davidson, 1988). FGF2 administered 
to dermal fibroblasts and keratinocytes may act in 
both an autocrine and paracrine fashion in 
promoting re-epithelialization during skin wound 
healing (Scott et al., 1991). In our previous study, 
prolonged FGF2 delivery by HCF also enhanced 
the skin regeneration (Bhang et al., 2011).
    The results of the in vitro GF release test and 
bioactivity test (Figure 1) show that HCF preserved 
GF activity and released them slowly. The release 
test showed that PRP-HCF exerted sustained 
release of HGF, VEGF, and FGF2, which are important 
GFs for angiogenesis and tissue regeneration 
(Tonnesen et al., 2000). The sustained release of 
GFs by HCF is attributed to electrostatic interactions 
between several types of GFs contained in PRP 
and heparin contained in HCF (Yang et al., 2010a, 
2010b). PRP-HCF also induced growth of HDF 
throughout the culture period, suggesting that HCF 
exerted sustained release of GFs contained in 
PRP and preserved the activity of the GFs. On the 
other hand, PRP alone did not have bioactivity on 
HDF growth likely due to rapid inactivation of GFs 
contained in PRP. Heparin contained in HCF may 
prevent potential loss of GF bioactivity. In the 
presence of heparin, degradation of bone morpho-
genetic protein (BMP-2) is blocked, and the half-life 
of BMP-2 in culture media is increased 20-fold 
(Zhao et al., 2006).
    The sustained delivery of GFs contained in PRP 
using HCF enhanced mouse full-thickness skin 
wound healing compared to delivery of GFs using 
either no carrier or fibrin (Figures 3-5). Based on 
histology, HCF-PRP group also showed shorter 
inter-SC distance than F-PRP and C-PRP groups 
(Figure 4D). This indicates that HCF-PRP promoted 
the recovery of normal skin structure. HCF-PRP 
group yielded faster epithelial closure than F-PRP 
and C-PRP groups (Figure 5A), indicating that 
HCF-PRP could accelerate keratinocyte migration 
to the wound site and reestablish the skin barrier, 
which can prevent the invasion of pathogens such 
as bacteria. HCF-PRP induced upregulation of the 
MMP-9 gene compared to no treatment, F-PRP, 
and C-PRP groups (Figure 5B). MMP-9 shows 
keratinocyte cell migration through the wound site 
(Tharakan et al., 2010), which explains the better 
epithelial closure in HCF-PRP group compared to 
the other groups. A study reported that FGF2 may 
act on keratinocytes and promote re-epithelialization 
during skin wound healing (Hebda et al., 1990). 
Thus, sustained release of FGF2 by HCF may 
enhance re-epithelialization efficacy of PRP. Previous 
studies have shown that applying HCF only to skin 
wounds has no stimulatory effect on wound healing 
(Bhang et al., 2011).
    The enhanced wound healing may be attributed, 
at least in part, to enhanced neovascularization in 
the wound beds (Tonnesen et al., 2000), which is 
likely due to sustained delivery of GFs contained in 
PRP using HCF. Neovascularization is necessary 
to sustain the newly formed granulation tissue in the 
wound region (Singer and Clark, 1999). Granulation 
tissue replaces the fibrin clot of the wound as 
phase transition occurs from inflammatory phase to 
proliferative phase (Baum and Arpey, 2005). 
Granulation tissue contains macrophages that provide 
GFs necessary for fibroplasia and angiogenesis, 
which in turn provide new ECM for cell ingrowth 
and supply oxygen and nutrients for cell metabolism 
(Singer and Clark, 1999). The enhanced neo-
vascularization by sustained delivery of GFs con-
tained in PRP has been also reported in a previous 
study demonstrating that sustained release of GFs 
in PRP using gelatin hydrogel enhances vessel 
density and perfusion in ischemic hind limbs in 
mice compared to treatment with PRP only (Bir et 
al., 2009). HCF- PRP group showed enhanced ne-
ovascularization in the repair tissues as compared 
to no treatment, F-PRP, and C-PRP groups 
(Figures 6 and 7). Neovascularization process in-
volves MMP (Raza and Cornelius, 2000). MMP-2 
and MMP-9 mediate neovascularization by endothelial 
cell migration as they degrade ECM (Schnaper et 
al., 1993; Raza and Cornelius, 2000; Kim et al., 
2010). MMPs are localized on endothelial cells by 
integrins such as αVβ3 (Brooks et al., 1996), and 
MMP expression is stimulated by GFs such as 
VEGF and FGF (Moses, 1997). VEGF and FGF al-
so stimulate the expression of integrins in endothe-
lial cells (Enenstein et al., 1992; Senger et al., 
1996, 1997). Sustained release of GFs from PRP 
by HCF upregulated MMP-9 expression (Figure 
5B), which may promote endothelial cell migration 
and, in turn, neovascularization.
    Although this study evaluated HCF-PRP as a 
wound healing material, limitations still exist. 
Firstly, the present study showed a superior effect 
of HCF-PRP on acute wound healing. However, 
clinical demand for newer therapeutic options is 
required more for chronic intractable wounds such 
as diabetic foot ulcer than acute injuries. PRP-HCF 
could be also effective for chronic wound healing, 
since the shortage of circulation around the chronic 
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wound results in a shortage of native GFs. 
Secondly, the present study did not clarify whether 
the GF-heparin complex or GF alone is released 
from HCF-PRP. There is a possibility that the 
GF-heparin complex may act as a stronger signal 
than GF only, similar to HS-GF complex (Schultz 
and Wysocki, 2009).
Methods
PRP preparation
Human blood was collected from healthy donors in an 
EDTA-coated container (BD VacutainerⓇ, Franklin Lakes, 
NJ). PRP was isolated as previously described (Bir et al., 
2009). The blood was centrifuged at 2,400 rpm for 10 min 
at room temperature. After discarding the upper plate-
let-poor plasma, the sample was further centrifuged at 
3,500 rpm for an additional 15 min, thereby separating the 
upper PRP layer and the lower red blood cells- and white 
blood cells-rich layer. The upper layer was collected care-
fully using an autopipette.
Preparation of HCF
HCF was prepared as previously reported (Yang et al., 
2010b). Heparin (molecular weight = 4,000-6,000, Sigma, 
St. Louis, MO) was covalently bonded to plasminogen-free 
fibrinogen (Sigma) using a procedure employing standard 
carbodiimide chemistry. HCF was formed by mixing hep-
arin-conjugated fibrinogen (40 mg/ml), normal fibrinogen 
(60 mg/ml) with factor XIII, aprotinin (100 KIU/ml), calcium 
chloride (6 mg/ml), and thrombin (500 IU/mg) in PBS. 
C-PRP gel was formed by mixing 100 μl of calcium chlor-
ide (6 mg/ml) and 100 μl of PRP. F-PRP gel was formed by 
mixing 100 μl of normal fibrinogen (60 mg/ml), thrombin 
(500 IU/mg), and calcium chloride (6 mg/ml) and 100 μl of 
PRP. HCF-PRP gel was prepared by mixing 100 μl of HCF 
and 100 μl PRP. The volume of PRP in HCF-PRP, C-PRP, 
or F-PRP was half of the total volume of the gels.
Release kinetics of GFs contained in PRP
The kinetics of VEGF, FGF2, and PDGF-BB release from 
various delivery systems were determined by ELISA. 
Either 500 μl of PRP alone or 1 ml of HCF-PRP, C-PRP, or 
F-PRP (n = 3 per group) containing 500 μl of PRP each 
was gelated and immersed in 2 ml microcentrifuge tubes 
(Corning Inc., New York, NY) containing 1 ml of PBS. The 
tubes were incubated at 37oC with continuous agitation. At 
various time points, the supernatant was collected, and the 
tubes were replenished with the same amounts of fresh 
PBS. The amounts of VEGF, FGF-2, and HGF in the su-
pernatants were determined using ELISA kits (R&D 
System, Minneapolis, MN).
Effect of GFs from PRP-loaded gels on HDF growth
The activity of GFs released from delivery systems was de-
termined by culturing HDFs in 6-well plates. PRP, C-PRP, 
F-PRP, or HCF-PRP (n = 3 per group), each containing 
250 μl of PRP, was placed in a 24 mm TranswellⓇ with a 
3 μm pore polyester membrane (Corning Inc.) under which 
HDF was cultured. Five hundred microliters of C-PRP, 
F-PRP, and HCF-PRP were gelated in a discoid shape. As 
a negative control, 250 μl of HCF gel without PRP was 
used. The medium was Dulbecco’s modified Eagle’s medium 
(DMEM, Gibco, Grand Island, NY) containing 1% pen-
icillin/streptomycin. One thousand HDFs per well were plat-
ed and cultured. The culture medium was changed every 4 
days. The cell number was counted every 3 days for 12 
days using a hemocytometer (Paul Marienfeld GmbH & 
Co., Lauda-Königshofen, Germany).
Wound treatment
Female athymic mice (BALB/c-nu, 4 weeks old; SLC, Tokyo, 
Japan) were anesthetized with xylazine (20 mg/kg) and 
ketamine (100 mg/kg). A 2.0×2.0 cm sized skin defect 
was made on the back of each mouse with surgical 
scissors. Epidermis, dermis, and SC were removed, and 
the muscle fascia was exposed. In order to prevent the 
wound by contracture, 8 sutures were placed at the border 
of the wound with 6-0 sutures (Ethicon, Somerville, NJ) 
and the wound margins were anchored to the underlying 
muscle fascia. The wounds were treated once with a total 
200 μl of PRP-HCF, C-PRP, and F-PRP (n = 7). C-PRP, 
F-PRP, or HCF-PRP was formed on the wounds by directly 
applying 100 μl of PRP and adding 100 μl of calcium chlor-
ide (6 mg/ml), normal fibrinogen (60 mg/ml), or HCF, re-
spectively, on each of the wounds. The concentrations of 
PDGF-BB, VEGF, and FGF2 are shown in Figure 1A. After 
gel formation, the wounds were covered with polyurethane 
film (Tegaderm, 3M Healthcare, St. Paul, MN). The films 
covering the wounds were changed every 4 days to take 
macroscopic pictures of the wounds. Mice whose wounds 
were treated with the film only served as a negative control 
(n = 7). The animals were individually housed after surgery. 
The animal study procedures were approved by the 
Institutional Animal Care and Use Committee at Seoul 
National University (SNU-100629-6).
Evaluation of wound healing
At 12 days, all mice were sacrificed. The wounds were 
sampled in full-thickness, including the underlying muscle. 
Half of each specimen was used for histological analysis, 
and the other half was used for reverse transcriptase 
(RT)-PCR and immunohistochemistry. The histological 
specimens were fixed in formalin, embedded in paraffin, 
sectioned transversely at a thickness of 4 μm, and exam-
ined with Masson’s Trichrome.
Morphometric analysis
The macroscopic wound area was quantified by process-
ing photographs taken at various time points by tracing the 
wound margin and calculating the pixel area relating it to 
the ruler using fine resolution computer mouse. The loca-
tion of the advancing margin of wound closure was defined 
as the grossly visible margin of epithelial migration toward 
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the center of the wound and over the granulation tissue 
bed. The wound area was calculated as the percentage of 
the initial wound area ([wound area at time] / [initial wound 
area]×100%). Microscopic tissue regeneration was de-
termined on Masson’s trichrome-stained tissue sections 
using a light microscope (KS400, Zeiss, Munich, 
Germany). Morphometric analysis was performed on digital 
images using the imaging software Image Pro Plus 6.0 
(Mediacybernetics, Silver Spring, MD). 
Immunohistochemistry
For immunohistochemical staining, samples embedded in 
OCT compound (Tissue-Tek 4583Ⓡ, Sakura Finetek USA 
Inc., Torrance, CA) were cut into 10-μm-thick sections at 
-22oC. To stain regenerated capillaries and arterioles, sec-
tions were immunofluorescently stained with vWF anti-
bodies (Abcam, Cambridge, UK) and anti-SM α-actin anti-
bodies (Abcam). The sections were also immunofluorescently 
stained with anti-involucrin antibodies (Abcam), which stain 
the stratum corneum and granulosum (Tharakan et al., 
2010), the more differentiated layers of the epithelium. 
vWF- and SM α-actin-positive signals were visualized with 
fluorescein-isothiocyanate-conjugated secondary antibodies 
(Jackson Immuno Research Laboratories, West Grove, 
PA). The staining signals for involucrin were visualized with 
rhodamine-conjugated and fluorescein-isothiocyanate-con-
jugated secondary antibodies (Jackson Immuno Research 
Laboratories). The sections were counterstained with 
4',6-diamidino-2-phenylindole (DAPI) and examined by flu-
orescence microscopy (IX71 inverted microscope; Olympus, 
Tokyo, Japan). Ten slides were randomly selected from the 
middle part of each sample for analysis. To count capil-
laries and arterioles in the regenerated regions, vessels 
were counted and calculated as vessel number per unit 
area (mm2). SM α-actin-positive vessels were counted as 
arterioles. The number of vWF-positive vessels minus the 
number of SM α-actin-positive vessels was taken as the 
capillary number.
RT-PCR 
Total RNA was extracted from the specimen with chloro-
form (Sigma) and precipitated with 80% (v/v) isopropanol 
(Sigma). After the supernatant was removed, the RNA pel-
let was washed with 75% (v/v) ethanol, air-dried, and dis-
solved in 0.1% (v/v) diethyl pyrocarbonate-treated water 
(Sigma). Reverse transcription was performed using 5 μg 
of pure total RNA and SuperScriptTM II reverse tran-
scriptase (Invitrogen), and the synthesized cDNA was am-
plified by PCR. PCR was carried out for 40 cycles of dena-
turation (94oC, 30 s), annealing (58oC, 45 s), and extension 
(72oC, 45 s) with a final extension at 72oC for 10 min. PCR 
products were visualized by electrophoresis on 1.5% (w/v) 
agarose gel followed by SYBRⓇ Safe DNA gel staining 
(Invitrogen). The products were analyzed using a gel doc-
umentation system (Gel Doc 1000, Bio-Rad, Hercules, CA). 
β-actin served as an internal control. The sequences of the 
primers were as follows: β-actin: forward primer, 5'-TGG 
ACT TCG AGC AAG AGA-3'; and reverse primer, 5'-ATC 
TCC TTC TGC ATC CTG-3', MMP-9: forward primer, 
5'-CTC AGA GAT TCT CCG TGT CCT GTA-3'; and re-
verse primer 5'-GAC TGC CAG GAA GAC ACT TGG 
TTA-3'.
Statistical analysis
Quantitative data were expressed as means±SD. Statistical 
comparisons were carried out using Student's t-test (SAS 
software, SAS Institute, Inc., Cary, NC). The value of P＜
0.05 was considered statistically significant.
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